falsefalse

Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer - Episode 7

Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer

,

Medical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer
    EP. 2: First-Line Treatment Options in HR+/HER2- Locally Advanced and Metastatic Breast Cancer and Challenges with Treatment Resistance
    EP. 3: Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway
    EP. 4: Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer
    EP. 5: Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291
    EP. 6: Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer
    Now Viewing
    EP. 7: Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer
    EP. 8: Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

    Related Content:

    Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast CancerUPMC Hillman Cancer CenterSarah Cannon Research InstituteClinicalBreast CancerInsightsVideo Series
    Comprehensive Biomarker Testing in Early-Stage NSCLC: Identifying Gaps, Challenges, and Strategies for Improvement
    Key Takeaways: CAR T in Real-World Clinical Practice
    Optimizing Molecular Testing, Diagnosis, and Workflow in Early-Stage NSCLC Through Multidisciplinary Collaboration
    x